Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1087

1.

Bleeding patterns with the 19.5 mg LNG-IUS, with special focus on the first year of use: implications for counselling.

Beckert V, Ahlers C, Frenz AK, Gerlinger C, Bannemerschult R, Lukkari-Lax E.

Eur J Contracept Reprod Health Care. 2019 Aug;24(4):251-259. doi: 10.1080/13625187.2019.1630817. Epub 2019 Jun 21.

PMID:
31223042
2.

HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.

Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium.

Lancet. 2019 Jul 27;394(10195):303-313. doi: 10.1016/S0140-6736(19)31288-7. Epub 2019 Jun 13. Erratum in: Lancet. 2019 Jul 27;394(10195):302.

3.

Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.

Thurman AR, Schwartz JL, Ravel J, Gajer P, Marzinke MA, Yousefieh N, Anderson SM, Doncel GF.

PLoS One. 2019 May 20;14(5):e0217229. doi: 10.1371/journal.pone.0217229. eCollection 2019.

4.

Brief Report: HIV Shedding in the Female Genital Tract of Women on ART and Progestin Contraception: Extended Follow-up Results of a Randomized Clinical Trial.

Kourtis AP, Wiener J, Hurst S, Nelson JAE, Cottrell ML, Corbett A, Chinula L, Msika A, Haddad LB, Tang JH.

J Acquir Immune Defic Syndr. 2019 Jun 1;81(2):163-165. doi: 10.1097/QAI.0000000000002011.

PMID:
31095006
5.

Six months response rate of combined oral medroxyprogesterone/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: a Korean Gynecologic-Oncology Group Study.

Kim MK, Seong SJ, Kang SB, Bae DS, Kim JW, Nam JH, Lim MC, Lee TS, Kim S, Paek J.

J Gynecol Oncol. 2019 Mar;30(2):e47. doi: 10.3802/jgo.2019.30.e47. Epub 2019 Jan 7.

6.

Effects of a levonorgestrel intrauterine system versus a copper intrauterine device on menstrual changes and uterine artery Doppler.

Rezk M, Elshamy E, Shaheen AE, Shawky M, Marawan H.

Int J Gynaecol Obstet. 2019 Apr;145(1):18-22. doi: 10.1002/ijgo.12778. Epub 2019 Feb 20.

PMID:
30706471
7.

Intrauterine Device Insertion Procedure Duration in Adolescent and Young Adult Women.

O'Flynn O'Brien KL, Akers AY, Perriera LK, Schreiber CA, Garcia-Espana JF, Sonalkar S.

J Pediatr Adolesc Gynecol. 2019 Jun;32(3):312-315. doi: 10.1016/j.jpag.2019.01.002. Epub 2019 Jan 8.

PMID:
30633980
8.

Five-Year Contraceptive Efficacy and Safety of a Levonorgestrel 52-mg Intrauterine System.

Teal SB, Turok DK, Chen BA, Kimble T, Olariu AI, Creinin MD.

Obstet Gynecol. 2019 Jan;133(1):63-70. doi: 10.1097/AOG.0000000000003034.

9.

Cervico-vaginal inflammatory cytokine alterations after intrauterine contraceptive device insertion: A pilot study.

Sharma P, Shahabi K, Spitzer R, Farrugia M, Kaul R, Yudin M.

PLoS One. 2018 Dec 4;13(12):e0207266. doi: 10.1371/journal.pone.0207266. eCollection 2018.

10.

Self-administered vaginal lidocaine gel for pain management with intrauterine device insertion: a blinded, randomized controlled trial.

Conti JA, Lerma K, Schneyer RJ, Hastings CV, Blumenthal PD, Shaw KA.

Am J Obstet Gynecol. 2019 Feb;220(2):177.e1-177.e7. doi: 10.1016/j.ajog.2018.11.1085. Epub 2018 Nov 13.

PMID:
30444982
11.

Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial.

Carvalho N, Margatho D, Cursino K, Benetti-Pinto CL, Bahamondes L.

Fertil Steril. 2018 Nov;110(6):1129-1136. doi: 10.1016/j.fertnstert.2018.07.003.

PMID:
30396557
12.

Assessment of biomarkers in women with endometriosis-associated pain using the ENG contraceptive implant or the 52 mg LNG-IUS: a non-inferiority randomised clinical trial.

Margatho D, Mota Carvalho N, Eloy L, Bahamondes L.

Eur J Contracept Reprod Health Care. 2018 Oct;23(5):344-350. doi: 10.1080/13625187.2018.1531117. Epub 2018 Oct 29.

PMID:
30372645
13.

Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial.

Papaikonomou K, Kopp Kallner H, Söderdahl F, Gemzell-Danielsson K.

Hum Reprod. 2018 Nov 1;33(11):2002-2009. doi: 10.1093/humrep/dey296.

PMID:
30295731
14.

The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women.

Elgart A, Zur AA, Mimrod D, Dror V, Bar-Ilan O, Korver T, Spiegelstein O.

Eur J Clin Pharmacol. 2019 Jan;75(1):41-49. doi: 10.1007/s00228-018-2549-7. Epub 2018 Sep 6.

PMID:
30191262
15.

Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.

Thurman AR, Schwartz JL, Brache V, Clark MR, McCormick T, Chandra N, Marzinke MA, Stanczyk FZ, Dezzutti CS, Hillier SL, Herold BC, Fichorova R, Asin SN, Rollenhagen C, Weiner D, Kiser P, Doncel GF.

PLoS One. 2018 Jun 28;13(6):e0199778. doi: 10.1371/journal.pone.0199778. eCollection 2018.

16.

A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement.

Bahamondes L, Brache V, Ali M, Habib N; WHO study group on contraceptive implants for women.

Contraception. 2018 Sep;98(3):181-187. doi: 10.1016/j.contraception.2018.05.009. Epub 2018 May 16.

PMID:
29777663
17.

Effect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trial.

Chinula L, Nelson JAE, Wiener J, Tang JH, Hurst S, Tegha G, Msika A, Ellington S, Hosseinipour MC, Mataya R, Haddad LB, Kourtis AP.

Contraception. 2018 Sep;98(3):193-198. doi: 10.1016/j.contraception.2018.05.001. Epub 2018 May 8.

18.

Satisfaction With the Intrauterine Device Insertion Procedure Among Adolescent and Young Adult Women.

Akers AY, Harding J, Perriera LK, Schreiber C, Garcia-Espana JF, Sonalkar S.

Obstet Gynecol. 2018 Jun;131(6):1130-1136. doi: 10.1097/AOG.0000000000002596.

19.

Low-dose LNG-IUS as Therapy for Endometrial Hyperplasia. A Prospective Cohort Pilot Study.

Sletten ET, Arnes M, Vereide AB, Ørbo A.

Anticancer Res. 2018 May;38(5):2883-2889.

PMID:
29715112
20.

Bleeding patterns for the Liletta® levonorgestrel 52 mg intrauterine system.

Schreiber CA, Teal SB, Blumenthal PD, Keder LM, Olariu AI, Creinin MD.

Eur J Contracept Reprod Health Care. 2018 Apr;23(2):116-120. doi: 10.1080/13625187.2018.1449825. Epub 2018 Mar 21.

PMID:
29560743

Supplemental Content

Loading ...
Support Center